Positive study results for AbbVie and Neurocrine
January 08, 2015 at 13:22 PM EST
AbbVie Inc. (Nasdaq:
ABBV) and Neurocrine Biosciences Inc. (Nasdaq: NBIX) reported positive
results from a Phase 3 clinical trial of elagolix in premenopausal women
with endometriosis. Shares of AbbVie rose 85 cents to $67.78 while Neurocrine Biosciences stock leaped $4.41 to $26.29.
